Tourette Syndrome Clinical Trial
Official title:
Brain Stimulation in Movement Disorders
Verified date | January 2020 |
Source | Birmingham and Solihull Mental Health NHS Foundation Trust |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Brain stimulation in movement disorders
This trial will explore the effects of very gentle electrical stimulation of the brain in
patients with movement disorders. Other studies have already been carried out and have shown
that brain stimulation may help to improve mental abilities and the symptoms of conditions
such as depression and stroke. The investigators will show whether this method can help with
symptoms such as memory and concentration problems in patients with movement disorder who
have mild to moderate problems with these mental abilities. The investigators will also look
at the effects of brain stimulation on movement symptoms and mood. These people will be
compared to healthy people to help us understand whether brain stimulation works differently
in healthy people and people with brain disorders.
This trial is being carried out at one centre in Birmingham. It is scheduled to begin in
September 2014 and will last for up to five years. As the study commences it is being funded
by Birmingham and Solihull Mental Health Foundation Trust and University of Birmingham. The
investigators plan to recruit up to a maximum of 200 individuals in this study.
Status | Completed |
Enrollment | 20 |
Est. completion date | September 2019 |
Est. primary completion date | September 2018 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Patients will have either Tourette syndrome (TS) diagnosed according to Diagnostic and Statistical Manual of Mental Disorders criteria or Huntington's disease (HD) diagnosed genetically - Controls will be generally healthy individuals not taking any psychoactive medications and without diagnosed psychiatric or serious medical conditions (e.g. history of seizures, heart disease, head injury) - 18-65 years of age for TS; 40-65 years of age for HD; 18-65 for controls - English as a first language Exclusion Criteria: - No current significant co-morbid psychiatric disorder (e.g. learning disability, schizophrenia) or medical condition which may contraindicate brain stimulation or magnetic resonance imaging (e.g. epilepsy, chronic heart disease, scalp skin conditions, metal skull implants). Mild symptoms of obsessive compulsive disorder, attention deficit hyperactivity disorder and/or mood disorders will be accepted as these are very common - No contraindications to MRI scanning (if they will be scanned) such as metal in the body, claustrophobia or seizure history - No complex medication regimes (e.g. combinations of multiple dopaminergic drugs plus selective serotonin reuptake inhibitors |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Department of Neuropsychiatry, BSMHFT The Barberry | Birmingham | West Midlands |
Lead Sponsor | Collaborator |
---|---|
Birmingham and Solihull Mental Health NHS Foundation Trust | University of Birmingham |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in cognitive function (working memory, response inhibition) | From baseline to five minutes after brain stimulation and from baseline to two weeks after stimulation (follow-up) | ||
Secondary | Change in motor symptom severity (tics/chorea) | From baseline to five minutes after brain stimulation and from baseline to two weeks after stimulation (follow-up) | ||
Secondary | Mood change (anxiety and depression questionnaire scores) | From baseline to five minutes after brain stimulation and from baseline to two weeks after stimulation (follow-up) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04851678 -
Longitudinal Impact of Stressors in Adults With Tourette Syndrome
|
||
Completed |
NCT02605902 -
Trial to Demonstrate the Efficacy and Safety of Internet-delivered Behavioral Treatment for Adults With Tic Disorders
|
N/A | |
Completed |
NCT04007913 -
Incorporating teleCBIT Into a Hospital-Based Tic Program
|
N/A | |
Completed |
NCT02900144 -
Modified Comprehensive Behavioral Intervention for Tics (M_CBIT)
|
N/A | |
Completed |
NCT02256475 -
Safety, Pharmacokinetics, and Pharmacodynamics of NBI-98854 in Children and Adolescents With Tourette Syndrome
|
Phase 1 | |
Completed |
NCT01329198 -
Brain Stimulation for the Treatment of Tourette Syndrome
|
N/A | |
Terminated |
NCT00952601 -
Pilot Study of the Modified Atkins Diet for Tourette Syndrome
|
Phase 1 | |
Enrolling by invitation |
NCT00355927 -
Sedation During Microelectrode Recordings Before Deep Brain Stimulation for Movement Disorders.
|
N/A | |
Completed |
NCT00206323 -
A Randomized, Placebo-controlled, Tourette Syndrome Study.
|
Phase 3 | |
Completed |
NCT00004376 -
Phase III Randomized, Double-Blind, Placebo-Controlled Study of Guanfacine for Tourette Syndrome and Attention Deficit Hyperactivity Disorder
|
Phase 3 | |
Completed |
NCT04498364 -
Extinction Learning in Adults With Tourette Syndrome
|
N/A | |
Completed |
NCT00755339 -
Role of the Sensory Experience in Generating Motor Tics in Tourette Syndrome
|
||
Completed |
NCT03325010 -
Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
|
Phase 2 | |
Not yet recruiting |
NCT06081348 -
Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
|
Phase 2 | |
Completed |
NCT01719523 -
Open-Trial of EPI-743 for Adults With Tourette Syndrome
|
Phase 1 | |
Completed |
NCT01702077 -
Neurofeedback for Tourette Syndrome
|
N/A | |
Completed |
NCT00231985 -
Effectiveness of Behavior Therapy and Psychosocial Therapy for the Treatment of Tourette Syndrome and Chronic Tic Disorder
|
Phase 2 | |
Completed |
NCT00206336 -
An Open-label Study to Determine the Efficacy and Safety of Topiramate in the Treatment of Tourette Syndrome.
|
Phase 3 | |
Terminated |
NCT03732534 -
Rollover Study for Continuing NBI-98854 Administration in Pediatric Subjects With Tourette Syndrome
|
Phase 2 | |
Completed |
NCT03625453 -
Study of ABX-1431 in Adult Patients With Tourette Syndrome or Chronic Motor Tic Disorder
|
Phase 2 |